Predictive genomic testing has the potential to usher in an era of personalized cancer care for patients. However, a recent study finds that not all physicians are eager to embrace the technology.
In September, GE and leading healthcare and financial partners launched a new healthymagination initiative focused on accelerating cancer innovation and improving care for 10 million cancer patients around the world by 2020 . The plan was announced in New York by GE’s CEO and Chairman Jeff Immelt to an audience of prominent cancer scientists and researchers, doctors, financial partners and employees of GE Healthcare. The company’s comprehensive initiative combines the strength of GE’s portfolio of integrated cancer technologies with collaboration between GE and new partners and data sources to help clinicians provide better, more personalized care.
Tyrosine kinases are signaling molecules that are frequently mutated as cells become tumorigenic. One of their responsibilities is regulating a cell’s growth based on the extracellular signals they receive. The presence of extracellular growth factors tells them to induce the cell to grow more rapidly, while a lack of oxygen or nutrients tells them to grow more slowly. When these kinases are mutated they make the cell grow uncontrollably, divorcing growth from the conditions outside the cell. In some cases, this mutation is what makes a cell cancerous.